Publications by authors named "ADAMOVICH A"

Delineating functionally normal variants from functionally abnormal variants in tumor suppressor proteins is critical for cancer surveillance, prognosis, and treatment options. BRCA1 is a protein that has many variants of uncertain significance which are not yet classified as functionally normal or abnormal. In vitro functional assays can be used to identify the functional impact of a variant when the variant has not yet been categorized through clinical observation.

View Article and Find Full Text PDF

Single nucleotide variants are the most frequent type of sequence changes detected in the genome and these are frequently variants of uncertain significance (VUS). VUS are changes in DNA for which disease risk association is unknown. Thus, methods that classify the functional impact of a VUS can be used as evidence for variant interpretation.

View Article and Find Full Text PDF

Unlabelled: Single nucleotide variants are the most frequent type of sequence changes detected in the genome and these are frequently variants of uncertain significance (VUS). VUS are changes in DNA for which disease risk association is unknown. Thus, methods that classify the functional impact of a VUS can be used as evidence for variant interpretation.

View Article and Find Full Text PDF
Article Synopsis
  • Pathogenic variants in the BRCA1 gene significantly increase the risk of hereditary breast and ovarian cancer, with many individuals identified carrying variants of uncertain significance (VUSs) through genetic testing.
  • The study assessed 2,271 and 1,427 BRCA1 variants for their roles in homology-directed repair (HDR) and cisplatin resistance (CR) using multiplexed DNA repair assays, revealing high consistency in results.
  • Findings indicate that functional characteristics of these variants align with known clinical significance, providing valuable resources for understanding BRCA1 VUSs and their impact on tumor suppression.
View Article and Find Full Text PDF

The BARD1 protein, which heterodimerizes with BRCA1, is encoded by a known breast cancer susceptibility gene. While several BARD1 variants have been identified as pathogenic, many more missense variants exist that do not occur frequently enough to assign a clinical risk. In this paper, whole exome sequencing of over 10,000 cancer samples from 33 cancer types identified from somatic mutations and loss of heterozygosity in tumors 76 potentially cancer-associated BARD1 missense and truncation variants.

View Article and Find Full Text PDF

PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.

View Article and Find Full Text PDF

Loss-of-function pathogenic variants in BRCA1 confer a predisposition to breast and ovarian cancer. Genetic testing for sequence changes in BRCA1 frequently reveals a missense variant for which the impact on cancer risk and on the molecular function of BRCA1 is unknown. Functional BRCA1 is required for the homology-directed repair (HDR) of double-strand DNA breaks, a critical activity for maintaining genome integrity and tumor suppression.

View Article and Find Full Text PDF

The role of the US Food and Drug Administration (FDA) in medical device regulation is important to device-driven specialties such as interventional radiology. Whether it is through industry-sponsored trials during the approval process for new devices or investigator-initiated research prospectively evaluating the role of existing devices for new or established procedures, interaction with the FDA is an integral part of performing significant research in interventional radiology. This article reviews the potential areas of interface between the FDA and interventional radiology, as understanding these areas is necessary to continue the innovation that is the hallmark of this specialty.

View Article and Find Full Text PDF

Results of estimation of the effect of a new hemicellulose-based anticoagulant drug on the reproductive function of white male rats are presented. No negative impact on the fertility and breed was observed for the drug administered in doses of 5 and 25 mg/kg. However, in a dose of 50 mg/kg, the new drug negatively affected spermatogenesis and decrease the reproductive function of male rats.

View Article and Find Full Text PDF

Purpose: To determine whether periprostatic treatment margins correlate with biochemical control in prostate brachytherapy patients with optimized intraprostatic dosimetry.

Methods And Materials: Nineteen biochemically failed brachytherapy patients were matched to 74 dosimetric and clinically equivalent nonfailures. The median followup time for the entire study population was 9.

View Article and Find Full Text PDF